A recent study indicates that people who stop using popular GLP-1 drugs like semaglutide or tirzepatide can put back on lost weight at a significantly accelerated pace than those who halt traditional lifestyle regimens.
Findings released in a leading health publication points out that while obese people can lose about a fifth of their body weight while on the medication, the weight comes back at an estimated rate of nearly a kilo each month once they quit.
"Individuals purchasing these medications should be aware of the risk of rapid weight regain when the treatment ends," stated expert Dr. Susan Jebb.
This pace of recovery implies a reversion to original weight in about 18 months.
Comparing Therapies
The research, which reviewed dozens of trials involving thousands of participants, compared the results of these new drugs with other pills.
Researchers emphasize that individuals who lose weight through diet and exercise usually see a less rapid creep back—perhaps 100 grams monthly—once they finish.
Explaining the Quick Regain
Doctors believe the mechanism of the jabs accounts for the accelerated weight return.
GLP-1 drugs mimic a body's own chemical called glucagon-like peptide-1, which moderates feelings of fullness.
"Long-term administration of GLP-1 concentrations far above than normal might result in the system to generate a reduced amount of its own natural hormone, and may also reduce responsiveness to its effects," noted Dr. Adam Collins, a nutrition expert.
"Withdrawal of this medication leads to appetite is unsuppressed, making overeating far more likely."
A Lifelong Issue?
Health authorities suggest the injections for individuals with obesity-related medical conditions, accompanied by prescribed lifestyle changes.
Professionals say that, due to the significant potential of weight regain, the treatment might need to be long-term.
This perspective is reinforced by drug manufacturers, who say that the findings "emphasize the chronic nature of obesity," comparing it to managing diseases like high blood pressure.
User Accounts
Users who have discontinued the jabs describe a intense resurgence of cravings.
"I experienced a trigger that goes on and you're instantly extremely hungry," said a patient.
The struggle is exacerbated if patients have not developed permanent lifestyle or habit changes during therapy.
Widespread Use
Survey data show that millions of people in the UK have tried these injections in the past year, with interest being substantial.
- Use is more common among women compared to men.
- The 40s and 50s demographic shows the greatest level of interest.
- Many access the medications through private healthcare rather than the NHS.
In conclusion, researchers caution that while GLP-1 drugs are powerful agents for weight loss, they are not a magic cure and maintained weight loss hinges on integrated behavioural support.
